FDA Approves Generic Gabapentin Oral Solution

Acella Pharmaceuticals announced that the FDA has approved Gabapentin oral solution 250mg/5mL, the generic equivalent of Pfizer's Neurontin oral solution 250mg/5mL.

Neurontin, an anticonvulsant, is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy, as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3–12 years, as well as treatment of postherpetic neuralgia in adults.

Gabapentin is structurally related to the neurotransmitter GABA (gamma-aminobutyric acid) but it does not modify GABAA or GABAB radioligand binding.  

For more information call (800) 541-4802 or visit www.acellapharma.com.